Literature DB >> 3570457

Immune response to the B oligomer of pertussis toxin.

J L Arciniega, D L Burns, E Garcia-Ortigoza, C R Manclark.   

Abstract

Immunization of mice with the B oligomer of pertussis toxin induced antibodies to the native toxin as measured by an enzyme-linked immunosorbent assay. These antibodies neutralized the ability of pertussis toxin to alter the morphology of Chinese hamster ovary cells. Furthermore, mice immunized with the B oligomer, when challenged with pertussis toxin, did not exhibit the leukocytosis normally associated with exposure to the toxin. These results demonstrate that the B oligomer, which does not contain the enzymatic activity of the holotoxin, can be used to induce a neutralizing antibody response and suggest that the B oligomer might be considered for use in acellular pertussis vaccines.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3570457      PMCID: PMC260480          DOI: 10.1128/iai.55.5.1132-1136.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

Review 1.  Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis.

Authors:  M Pittman
Journal:  Rev Infect Dis       Date:  1979 May-Jun

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Role of the A subunit of pertussis toxin in alteration of Chinese hamster ovary cell morphology.

Authors:  D L Burns; J G Kenimer; C R Manclark
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

5.  Evidence of whooping-cough-vaccine efficacy from the 1978 whooping-cough epidemic in Hertfordshire.

Authors:  M A Church
Journal:  Lancet       Date:  1979-07-28       Impact factor: 79.321

6.  Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis.

Authors:  Y Sato; K Izumiya; H Sato; J L Cowell; C R Manclark
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

Review 7.  Actions of cholera toxin and the prevention and treatment of cholera.

Authors:  J Holmgren
Journal:  Nature       Date:  1981-07-30       Impact factor: 49.962

8.  Diphtheria-pertussis-tetanus vaccine: reactogenicity of commercial products.

Authors:  R M Barkin; M E Pichichero
Journal:  Pediatrics       Date:  1979-02       Impact factor: 7.124

9.  Pertussis.

Authors:  L C Olson
Journal:  Medicine (Baltimore)       Date:  1975-11       Impact factor: 1.889

10.  Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis.

Authors:  J J Munoz; H Arai; R L Cole
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

View more
  22 in total

1.  Properties of pertussis toxin B oligomer assembled in vitro from recombinant polypeptides produced by Escherichia coli.

Authors:  W N Burnette; J L Arciniega; V L Mar; D L Burns
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

2.  Identification of linear B-cell determinants of pertussis toxin associated with the receptor recognition site of the S3 subunit.

Authors:  M A Schmidt; B Raupach; M Szulczynski; J Marzillier
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

3.  Properties of the B oligomer of pertussis toxin.

Authors:  L Nencioni; M G Pizza; G Volpini; M T De Magistris; F Giovannoni; R Rappuoli
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

4.  Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin.

Authors:  J L Arciniega; R D Shahin; W N Burnette; T D Bartley; D W Whiteley; V L Mar; D L Burns
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

5.  Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.

Authors:  P Boucher; H Sato; Y Sato; C Locht
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

Review 6.  Pertussis: the disease and new diagnostic methods.

Authors:  R L Friedman
Journal:  Clin Microbiol Rev       Date:  1988-10       Impact factor: 26.132

7.  Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin.

Authors:  R Antoine; C Locht
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

8.  Pertussis holotoxoid formed in vitro with a genetically deactivated S1 subunit.

Authors:  T D Bartley; D W Whiteley; V L Mar; D L Burns; W N Burnette
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  Identification of B-cell epitopes on the S4 subunit of pertussis toxin.

Authors:  P H Ibsen; A Holm; J W Petersen; C E Olsen; I Heron
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

10.  Immune response to dimeric subunits of the pertussis toxin B oligomer.

Authors:  S Z Hausman; D L Burns; V C Sickler; C R Manclark
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.